CoChat

Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells

Open access

Published version of a preprint

The DOI matches its Crossref record; 50 of the 53 references it cites were found in a registry or an index.

Abstract

PURPOSE: Targeting oncogenic receptors with antibodies has been thought to suppress tumor growth mainly by interrupting oncogenic signals. Recently, the essential role for adaptive immunity, and CD8(+) T cells in particular, has been established as a major factor for anti-HER2/neu-mediated tumor regression. However, the role of CD4(+) T cells is still being defined. The purpose of this study was to explore whether and to what extent CD4(+) T cells are involved in mediating the effects of anti-HER2/neu therapy. EXPERIMENTAL DESIGN: The role of CD4(+) T cells was examined using a transplant model of the rat HER2/neu-overexpressing cell line TUBO. Tumor-bearing mice were treated with anti-neu therapy in conjunction with CD4 depletion or CD40L blockade. The effects of CD4 depletion on the antitumor response were examined by tumor growth analysis and enzyme-linked immunospot (ELISPOT). RESULTS: In addition to CD8(+) T cells, CD4(+) T cells are also essential for anti-neu antibody-mediated tumor regression, but B cells are not required. The role for CD4(+) cells is necessary throughout anti-neu therapy and not limited to helping CD8(+) T cells. Expression of IFN-γ is necessary for anti-neu therapy and IFN-γ induces MHC-II expression in TUBO cells promoting direct recognition by CD4(+) T cells. Furthermore, intratumoral depletion of CD4(+) T cells or blockade of the activating cell-surface protein CD40L inhibits the antitumor response. CONCLUSIONS: This study reveals the essential role of CD4(+) T cell for anti-neu-mediated tumor regression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-2522

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 66

Metadata

Authors
Mortenson, E. D., Park, S., Jiang, Z., Wang, S., & Fu, Y.-X.
Affiliations
Inje University (KR)
Corresponding author
Fu, Yang-Xin
Venue
Clinical Cancer Research
Published
2013-03-14
Volume
19
Issue
6
Pages
1476-1486
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2113404235
Cited by
66
References
53
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 10 · 2022: 4 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 4 · 2015: 6 · 2014: 8
FWCI
3.22
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (CA141975, CA97296, R01CA141975, R01CA134563, P01CA097296)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
CD4+ T cells, HER2/neu, CD4 depletion, CD8+ T cells, interferon-gamma, MHC class II expression, antitumor immunity, B cells
MeSH terms
Animals, Antibodies, B-Lymphocytes, Humans, Immunotherapy, Interferon-gamma, CD4-Positive T-Lymphocytes, Mammary Neoplasms, Animal, CD8-Positive T-Lymphocytes, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Cell Line, Tumor, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-2522
The paper
Mortenson, E. D., Park, S., Jiang, Z., Wang, S., & Fu, Y.-X. (2013). Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-2522

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.